Avenue de l'Hôpital, 1
Imcyse is a clinical-stage biotech company headquartered in Liège, Belgium, created in 2010 as a spin-off of the Catholic University of Leuven (KULeuven). Numerous proof of concept studies have been completed in animal models for type 1 diabetes, multiple sclerosis, myasthenia gravis, allergic diseases, prevention of graft rejection and blocking of immunogenicity to viral vectors. Imcyse’s technology and results are protected by a robust, international intellectual property portfolio.
CEO and CMO: Pierre Vandepapeliere
CFO: Guillaume de Viron
13 articles with Imcyse
Biopharma and life sciences companies from around the globe provide updates on their pipelines and businesses.
Imcyse Raises Additional EUR 21.3 Million in Series B Financing Round - Pfizer Joins as Newest Shareholder
Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the treatment of severe autoimmune diseases, announced that it has concluded a Series B extension financing round, raising EUR 21.3 million.
Pfizer struck a collaboration and licensing agreement with Belgium-based Imcyse for a rheumatoid arthritis program, which is based on that company’s Imotope technology.
Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the treatment of severe autoimmune diseases, today announced the first patients treatment in the IM CY-0098 proof of Action in T ype 1 Diabetes (T1D) (IMPACT) study with IMCY-0098.
Imcyse Enters into Research Collaboration and License Agreement for its Imotope(TM) Technology with Pfizer in Rheumatoid Arthritis
Imcyse and Pfizer to collaborate to develop Imotope TM candidates to potentially treat Rheumatoid Arthritis Pfizer to lead clinical development and commercialization activities
Company’s insulin-based Imotope™ IMCY-0098 shows excellent safety profile and promising clinical trends
Company’s multiple sclerosis Imotope™ shows promising preclinical efficacy and histology results while eliciting immune responses supporting the proposed mode of action and providing proof of concept
Company’s insulin-based Imotope™ IMCY-0098 shows excellent safety profile and promising clinical trends while eliciting immune responses supporting the proposed mode of action
Company strengthens board ahead of trial results in type 1 diabetes patients and expansion of indications for its proprietary Imotope™ technology
Proceeds will facilitate clinical development of Imcyse’s technology in type 1 diabetes, multiple sclerosis and other indications
IMCYSE SUCCESSFULLY COMPLETES PATIENT ENROLLMENT IN FIRST-IN-HUMAN PHASE 1B STUDY IN TYPE 1 DIABETES
Imcyse, who develop active specific immunotherapies for the treatment and prevention of severe chronic diseases, today announces the successful enrolment of 41 patients with recent-onset type 1 diabetes into its first-in-human Phase 1b study.
Under the terms of the agreement, Pfizer will provide an undisclosed amount to fund the research activities, and Pfizer has an exclusive option to negotiate a license agreement for a limited period following the research activities.
The trial is now recruiting patients at 15 clinical sites in four European countries and should open soon in France.